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a  b  s  t  r  a  c  t
Syndrome  differentiation  (Bian  Zheng)  in  traditional  Chinese  medicine  (TCM)  is  the  comprehensive  anal-
ysis of clinical  information  gained  by  the  four  main  diagnostic  TCM  procedures:  observation,  listening,
questioning,  and  pulse  analysis,  and  it  is  used  to  guide  the  choice  of  treatment  either by  acupuncture
and/or  TCM  herbal  formulae,  that is,  Fufang.  TCM  syndrome  differentiation  can  be used for  further  strati-eywords:
yndrome differentiation
raditional Chinese medicine
ﬁcation of  the  patients’  conditions  with  certain  disease,  identiﬁed  by  orthodox  medical  diagnosis,  which
could  help  the  improvement  of  efﬁcacy  of  the  selected  intervention.  In  modern  TCM  research  it is  possible
to  integrate  syndrome  differentiation  with  orthodox  medical  diagnosis  leading  to  new  scientiﬁc  ﬁndings
in  overall  medical  diagnosis  and  treatment.  In  this  review,  the  focus  is to screen  published  evidence  on  the
role  of  syndrome  differentiation  in  modern  TCM  research  with  particular  emphasis  on  basic  and  clinical
research  as  well  as, pharmacological  evaluation  of  TCM  herbal  formulary  for drug  discovery.. Introduction
Currently traditional Chinese medicine (TCM) is an essential part
f the healthcare system in several Asian countries, and is con-
idered a complementary or alternative medical system in most
estern countries (Jiang et al., 2010a). The general practice of
CM depends on the accurate diagnosis and treatment procedures
nown as Bian Zheng Lun Zhi (syndrome differentiation followed
y treatment procedures). Syndrome differentiation is one of most
mportant concepts in the practice of TCM that consists of a series of
iagnostic procedures. Syndrome differentiation is different from
he conventional diagnosis methodology used in orthodox medi-
al practice. It is the process of comprehensive analysis of clinical
nformation obtained by the four main diagnostic TCM procedures:
bservation, listening, questioning, and pulse analyses. It is used to
uide the choice of TCM treatment using acupuncture and or TCM
erbal formulae, that is, Fufang. Thus the complete TCM process
s known as Bian Zheng Lun Zhi,  “Treatment based on syndrome
ifferentiation”. Correct TCM syndrome differentiation is the most
∗ Corresponding author at: China Academy of Chinese Medical Sciences, Nnaxi-
ojie 16#, Dongzhimennei, Beijing 100700, China. Tel.: +86 1064067611;
ax: +86 1084032881.
∗∗ Corresponding author at: Locked Bag 1797, Penrith, NSW 2751, Australia.
el.: +61 291141485; fax: +61 246203291.
E-mail addresses: lap64067611@126.com, lap@jzjt.com (A. Lu),
elvin.chan@sydney.edu.au (K. Chan).
1 Prof. Aiping Lu is working as Dean and Chair Professor in the School of Chinese
edicine, Hong Kong Baptist University from February, 2012.
378-8741© 2012 Elsevier Ireland Ltd. 
oi:10.1016/j.jep.2012.01.033
Open access under CC BY-NC-ND license.© 2012 Elsevier Ireland Ltd. 
important principle that guides the prescribing of Chinese herbal
formulae (Bao et al., 2010). It is possible to integrate TCM syndrome
differentiation and biomedical diagnosis in modern clinical prac-
tice. As shown in Fig. 1, diseases diagnosis shown in the transversal
way  for patient classiﬁcation and TCM syndrome differentiation
shown in the longitudinal way  indicate a cross relationship. A
patient can suffer from 2 or more diseases at same time, and one
disease can show 2 or more TCM syndromes. Similarly a patient
can show a mixture of TCM syndromes (2 or more syndrome),
and one TCM syndrome can be shown in different diseases. More-
over, syndrome differentiation is dynamic, and one syndrome could
be altered after TCM treatment according to the previous TCM
diagnostic pattern (symptoms, signs, tongue appearance and pulse
feelings).
The information obtained from syndrome differentiation,
including symptoms, pulse feelings and tongue appearance, is often
considered to be subjective. Patients’ responses to treatment and
their feelings can be recorded objectively in terms of patients’
reported outcomes (PROs), using instruments such as the scaling
ruler and questionnaires (Zhao and Chan, 2005). Recently TCM syn-
dromes were detected and veriﬁed in many diseases, including
Fibromyalgia Syndrome (Aliyev et al., 2010), amnestic mild cog-
nitive impairment and Alzheimer’s dementia (Miao et al., 2009),
hyperlipidaemia (Xue et al., 2010), gastric mucosal dysplasia (S.W.
Shen et al., 2011), thoracic diseases (Fu et al., 2011). Some corre-
Open access under CC BY-NC-ND license.lations between certain TCM syndrome and the disease were also
validated: the association between Shen (kidney) deﬁciency syn-
drome and postmenopausal osteoporosis (Chen et al., 1999), Xue
Yu (blood stasis) syndrome and coronary heart disease (Chen et al.,
M. Jiang et al. / Journal of Ethnopharmacology 140 (2012) 634– 642 635
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dig. 1. Concept of TCM syndrome differentiation and its correlations to biomedical d
arameters, and they can be linked to each other as shown; TCM syndrome also ex
011). Such observations have provided the substantial evidence
or the objectiveness of TCM syndrome differentiation.
TCM has its origins in China and the information for the TCM
yndrome differentiation is used in the past by the Chinese based
n the Chinese cultural development and understanding of TCM
nd its philosophies. The medical service based on TCM syndrome
ifferentiation may  be difﬁcult to be understood in the west, but in
he recent years where TCM practice outside China is widespread,
he TCM concepts have been adopted and practised gradually.
owever scientists in the west may  not be familiar with the intri-
acies of the syndrome differentiation and have generally focused
n phytochemical approaches on Chinese materia medica (CMM)
ith no reference on TCM syndrome differentiation research. Yet
ecently researchers outside China have demonstrated that the
CM syndromes can be observed in patients who are not of Chi-
ese origin. For instance, evidence was observed in the distribution
f similar TCM syndromes in Australian and Chinese women with
rimary dysmenorrhoea (Zhu et al., 2009); the Shen deﬁciency syn-
rome could be diagnosed in both German and Chinese menopausal
omen under the same diagnostic criteria (Rampp et al., 2008).
CM syndrome differentiation, if adopted as the diagnostic method
or the substantial part in modern TCM research, would lead to
ew scientiﬁc ﬁndings for medical sciences. In this review, we have
xplored its roles on modern TCM research and particularly focused
n its innovative impacts on medical research.
. Syndrome differentiation and modern research in TCM
iagnosis
One TCM syndrome differentiation can be observed in different
iseases as identiﬁed by western medicine (WM),  and differ-
nt syndrome differentiation can be shown in one WM-disease
biomedical disease). Thus it is not necessary to have a “one to
ne” correlation between the TCM syndrome and the biomedi-
al disease. In the clinical practice in China, both the biomedical
iagnosis for the disease and TCM syndrome differentiation are
ften incorporated, and the correlation between the biomedical
isease and TCM pattern is considered as the most important
pproach for modern TCM diagnosis research. Fig. 2 indicates how
he correlation between TCM syndrome differentiation (e.g. tongue
ppearance or pulse feeling) and the biomedical parameters (the
iagnosis information obtained from laboratory parameters and diagnosis. TCM syndrome and biomedical disease are classiﬁed basing on different
transitional changes during the treatment of the illness.
omics/biomarkers data related to the biomedical disease) can be
explored and further focused.
Considerable achievements have been made in correlating TCM
syndromes differentiation with measurable modern biomedical
indexes. The observations include: the linkage between sex hor-
mones and Shen deﬁciency syndrome was identiﬁed in chronic
nephritis (Zhang et al., 1990); between C-reactive protein and
Han/Re (cold/hot) syndrome in rheumatoid arthritis (RA) (Zhao
et al., 2006); between Qi-Yin deﬁciency syndrome in type 2 diabetes
mellitus patients (Xie et al., 2011); between carotid intima–media
thickness (IMT), triglyceride (TG) and blood rheology with certain
TCM syndrome (Lei et al., 2009); between blood stasis syndrome
score with 24-h urine protein ration, cholesterol, estimation of
glomerular ﬁltration rate (eGFR) in the primary glomerular diseases
(Li et al., 2009); between the bone mineral density and Shen deﬁ-
ciency syndrome in chronic obstructive pulmonary disease (COPD)
(Wang et al., 2005); between serum level of eosinophil cationic
protein in asthmatic patients and the development of “heat” syn-
drome manifestations (Hsu et al., 2003); between the decrease in
skin electrical conductance and the severity of Qi deﬁciency syn-
drome (Yu et al., 1998). More studies are in progress to explore the
correlations between TCM syndrome and the biological indexes.
We  believe that, following the use of data mining techniques and
bioinformatics approaches, the biological basis of TCM syndrome
would be further clariﬁed.
Systems biology approaches have recently been innovatively
utilized in the TCM syndrome differentiation studies. Systems
biology is similar to the views of the holistic approaches and
syndromes differentiation of TCM. It has been pointed out these
systems biology-based diagnostic principles can be used as pil-
lars of the bridge between TCM and biomedicine (Xue et al., 2006;
van der Greef et al., 2010). From the view of the gene expres-
sion proﬁle, the TCM syndrome differentiation has close intrinsic
relations with not only the difference of gene expression but
also the gene polymorphisms. Therefore, applying the advanced
microarray and sequencing techniques can help clarify the bio-
logical basis of TCM syndrome (Xue et al., 2006). By using the
microarray, RT-PCR and ELISA technologies, it was  explored that
Shen Yang deﬁciency syndrome is involved in special SNP linkage
disequilibrium (LD) in the intragenic level (Ding et al., 2009b), and
the marked low level of energy output in Shen Yang deﬁciency
syndrome may  be primarily attributed to the insufﬁcient activ-
ity of the MAPK pathway (Ding et al., 2009a).  The correlation of
636 M. Jiang et al. / Journal of Ethnopharmacology 140 (2012) 634– 642
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dig. 2. Application of TCM syndrome differentiations in modern innovative research
ppearance and pulse feeling) and biological parameters in biomedicine, or between
n  biomedicine.
nﬂammatory- and immune-related genes with coronary heart dis-
ase (CHD) patients of blood-stasis syndrome was revealed at the
evel of nucleic acid, and the target gene IL-8 could play a role
n the pathology of CHD with blood-stasis syndrome (Ma  et al.,
009). The cold syndrome was discovered to be possibly caused by
he physiological imbalance and/or the disorder of metabolite pro-
esses by the microarrays technology (Yang et al., 2007). Similarly,
 wide range of metabolomics analytical techniques are widely
sed in the modern research of TCM syndrome (Liang et al., 2010).
or example, the metabolomics method, ultra performance liquid
hromatograph/time of ﬂight mass spectrometer (UPLC/TOF-MS)
as successfully used in evaluating the animal model of TCM syn-
rome differentiation (Tong et al., 2011). A urinary metabolomics
ethod based on ultra-performance liquid chromatography cou-
led with mass spectrometry (UPLC/MS) was developed to study
etabolomic characters of the ‘Shen Yang deﬁciency syndrome’ rats
X. Lu et al., 2011). By metabolite proﬁles measured in plasma using
C/MS, molecular differences between the Cold and heat syndrome
n RA patients were found, which suggest differences in apoptotic
ctivity (van Wietmarschen et al., 2009). Using the GC/TOF-MS-
ased metabolomic method, the metabolites contributing most to
he classiﬁcation between the Xin blood stasis obstruction and Qi-Yin
eﬁciency syndrome rats were identiﬁed as the potential biomark-
rs (Yan et al., 2009). A urinary metabolomics method based
n the ultra-performance liquid chromatography combined with
uadrupole time-of-ﬂight tandem mass spectrometry (UPLC Q-TOF
S)  was used to evaluate the efﬁcacy and study the mechanism of
CM herbal preparation in treating the blood stasis syndrome (Zhao
t al., 2008). Proteomics has recently received extensive atten-
ion in the area of medical diagnosis and drug development, and
he proteomics data could also contribute to the TCM syndrome
ifferentiation research. We  believed that with further devel-
pment of analytical techniques, systems biological approaches
nd omics data will greatly promote TCM syndrome differenti-
tion research and be beneﬁcial to the modernization of TCM
iagnosis.M. The correlation can be applied either between TCM symptoms (including tongue
yndrome (assemblages of clinical manifestation) and omics parameters/biomarkers
The “correlation exploration” studies between TCM syndrome
differentiation and biomedical disease not only elucidate the bio-
logical basis for TCM syndrome differentiation, but also can help
innovative study in biomedicine, and more importantly help the
further accurate stratiﬁcation of patients for intervention selec-
tion by fully integrating of the TCM syndrome differentiation and
biomedical diagnosis.
3. Syndrome differentiation and modern clinical research
in TCM
More and more clinical trials of TCM have been conducted and
reported in China and abroad in the last decade with diversiﬁed
results (Jiang et al., 2010a).  The key issue in clinical research in TCM
is how to apply TCM syndrome differentiation in the clinical trial
design. TCM syndrome differentiation, as a method of patient strat-
iﬁcation, could change clinical trial strategy and help design better
clinical trials. This could be included in the clinical trial, as TCM
syndrome differentiation, can help choose the most appropriate
patients for the intervention. The concept behind TCM syndrome
differentiation and biomedical disease based efﬁcacy evaluations
may  optimize clinical trial design by identifying the responsive
cases which might be categorized in a certain TCM syndrome dif-
ferentiation. Fig. 3 indicates, in a clinical trial focusing on a disease,
there will always be the responsive and non-responsive cases to
one intervention. The comparison analysis between the responsive
and non-responsive cases can help detect the effectiveness related
symptoms and signs (which might be different from typical TCM
syndrome differentiation but homologous with and rooted from
TCM syndrome differentiation). Then a next round of clinical trial
can be conducted focusing on this subgroup of patients with the
positively related symptoms and signs as part of inclusion crite-
ria. We  can therefore anticipate that a higher effective rate would
be obtained in the second round of clinical trial since the patients
have been further stratiﬁed with the responsive related factors. This
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Fig. 3. Application of the TCM syndrome differentiation in clinical trial design. The left portion illustrates the intervention with TCM syndrome can be obtained from a clinical
trial  by comparing the differences between responsive cases and non-responsive cases, and the incorporation of the TCM syndrome information for further veriﬁcation in
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ndication after incorporation of TCM syndrome differentiation via the new clinical
nnovative clinical trial design can also be used for the clinical efﬁ-
acy evaluation of “old” drug to “renew” its indication (the right
art in Fig. 3). Recently a two-stage clinical trial of TCM therapy
or the management of RA has been designed (Zhang et al., 2011).
he stage one trial is an open-label trial and aims to explore what
roups of TCM information (such as symptoms) correlates with bet-
er efﬁcacy, and the stage two trial is a randomized, controlled,
ouble-blind clinical trial that incorporates the efﬁcacy-related
nformation identiﬁed in the stage-one trial into the inclusion cri-
eria. This design, though not deﬁning the TCM syndrome criteria,
oes include TCM syndrome differentiation concept.
In the clinical studies which employed TCM syndrome differ-
ntiation in the design, the desirable outcomes are found easier
o be achieved. For instance, in a double-blinded and randomized
linical trial, Fufangkushen enteric-coated capsule was proved to
e similarly effective and safe in the treatment of active ulcerative
olitis (UC) with TCM syndrome of damp-heat accumulation inte-
ior compared with a mesalamine enteric-coated tablet, and it even
ndicated preferable effect in the treatment of UC with inﬂamed
rea of the left hemicolon (Gong et al., 2011). In a prospective RCT,
anreqing Injection was proved to be able to improve the TCM signs
nd symptoms in the patients with acute exacerbation of chronic
bstructive pulmonary disease and TCM syndrome of retention of
hlegm and heat in Fei (Lung) (Li et al., 2010). Good effectiveness was
bjectively shown in the TCM treatment of children’s respiratory
yncytial viral pneumonia with phlegm-heat blocking Fei (Lung) syn-
rome in 206 children with a single-blinded multi-center, blocked,
andomized and parallel-controlled trial (Yang et al., 2009). In a
08 patients with psoriasis of blood-heat syndrome clinical study, a
ew Pulian Ointment (NPLO) showed a reliable therapeutic efﬁcacy
nd good safety for the treatment of psoriasis with TCM blood-heat
yndrome (Zhou et al., 2009). Another RCT proved the deﬁnite ther-
peutic effect and high safety can be achieved in using the TCM
herapy to treat RA with syndrome of damp-heat obstruction (H.B.
hen et al., 2011). A clinical investigation indicated that a more
ffective treatment rate could be achieved for RA patients when the effectiveness of an old drug, the old drug can be assessed to have more speciﬁc
esign.
co-diagnosed and treated based on their TCM syndrome differen-
tiation classiﬁcation (Zha et al., 2006). Though some clinical trials
and systematic reviews reported that it was  difﬁcult to show rig-
orous evidence for the effectiveness and safety of herbal medicine
(M.M.  Zhang et al., 2004; Chen et al., 2006; Leung et al., 2006), ran-
domized controlled clinical trials (RCTs) with speciﬁc assessment
criteria and diagnostic criteria are considered as being able to close
the gap between TCM and evidenced-based medicine (Zheng et al.,
2011). Therefore the incorporation of TCM syndrome differenti-
ation for further stratiﬁcation of the patients could improve the
efﬁcacy of a certain intervention in clinical practice.
The safety evaluation of a TCM intervention can be conducted
basing on the same principle. Through the thousands of years of
experience based practice, a full-grown TCM intervention usually
possesses a good safety proﬁle when used for its corresponding
TCM syndrome differentiation. Some symptoms are proved to be
predictive factors/risk factors for the drug adverse reactions (ADRs)
in RA patients treated with both TCM and biomedical combina-
tion therapy (Jiang et al., 2011b), and there have been documented
evidence showing correlations between gastrointestinal ADRs with
clinical efﬁcacy in RA patients treated with biomedical combination
therapy (Jiang et al., 2010b).  Thus the evaluation of TCM treatment
efﬁcacy and safety should focus on a speciﬁc subgroup of patients
with its corresponding TCM syndrome differentiation.
4. Syndrome differentiation and modern pharmacological
research in TCM
The clinical application of Chinese herbal medicine (CHM)
should be based on syndrome differentiation in TCM, and the
pharmacological evaluation of CHM should be also based on the
TCM syndrome differentiation. To clarify the CHM pharmacologi-
cal activity is not only the requirement for TCM globalization, but is
also important for guiding the clinical application of CHM. Thus the
method of characterizing of the TCM syndrome differentiation in
animal disease models becomes the key issue in pharmacological
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valuation. In the past years, some studies have reported that some
onditions induced by chemicals could be considered having sim-
lar TCM syndrome differentiation since the conditions showed
ertain clinical manifestations similar to the patients with the TCM
yndrome differentiation, and the condition could be reversed by
he corresponding CHM. For example, TCM Pi deﬁciency (Pi Xu) rat,
nduced by reserpine administration, could be treated with the
izhong Pill which can reinforce the deﬁcient Pi (Zhao et al., 2011).
odents with liver injury induced by carbon tetrachloride could be
egarded as suffering from the dampness-heat syndrome (Cao et al.,
009). A novel mice model induced by chronic intermittent hypoxia
howed similar symptoms and signs accorded with the clinical fea-
ures of Deﬁciency of both Qi and Yin syndrome (Chai et al., 2010).
ats with subcutaneous tumor of pancreatic cancer can be regarded
s suffering from syndromes of Damp heat (Shi-Re) and Pi deﬁciency
Dai et al., 2010). Based on the animal models with induced TCM
yndrome differentiation, pharmacological evaluations have been
onducted on CHM. Using the Qi deﬁciency and blood stasis syn-
rome rats model, the effects of Buyang Huanwu decoction on CHD
ere proved to be associated with the inhibition of C-reactive pro-
ein (CRP) and vascular endothelial regulators (Zhang et al., 2010).
ore directions on how to integrative TCM syndrome and biomed-
cal disease in animals have been conducted (Chai et al., 2009) and
he establishment of the disease with TCM syndrome differentia-
ion induced model could provide new concepts and method for
valuation of CHM (Ma and Zhai, 2010).
However the TCM syndrome differentiation is not only
omplicated, but also based on the information generated by
xperience-based TCM diagnostic methods mainly from diagno-
is through interrogation. Thus the pharmacological evaluation on
HM using these types of animal models could provide an alterna-
ive way. However it is necessary to develop more TCM syndrome
ifferentiation animal models based on the phenotype clinical
anifestations, and veriﬁed with the positive responses induced
y the TCM syndrome differentiation corresponding CHM. On the
ther hand, following the development of biomedicine, one impor-
ant way to clarify the TCM syndrome differentiation characteristics
f the animal disease model in the pharmacological evaluation
s to compare the differences between the responsive and non-
esponsive animals to a certain intervention, and to ﬁnd out the
esponsiveness-related biomedical characteristics, which can be
egarded as the essentials of the corresponding TCM syndrome dif-
erentiation. The biomedical characteristics can then be applied as
he text parameters for the pharmacological evaluation of a related
HM.
. Syndrome differentiation and modern new drug
iscovery in TCM
In orthodox medical practice any agent intended for human use
s a prescribed drug often consists of a single chemical compound
or the treatment of a speciﬁc disease diagnosed by biomedical
ethod. In TCM practice after diagnosis of patient’s conditions
ccording to speciﬁc syndrome differentiation, multiple compo-
ent Fufang consisting of several CMM  is prescribed to restore
he patient’s imbalanced conditions. The multiple compounds in
ufang, targeting on the biological network within the human body
an be analysed for new drug discovery if their concerted actions
an be recorded in terms of network pharmacology that links with
he biological networks of disease, the drug and drug-disease inter-
ction, and could provide the leads of becoming the next paradigm
n drug discovery as described by Hopkins (2007).  Hence new drugs
an be discovered from the “old” drugs if they can be redeﬁned
ith the newly prescribed conditions which are based on the inte-
ration of biomedical disease and TCM syndrome differentiation.acology 140 (2012) 634– 642
Syndrome differentiation should be taken into consideration in
new drug discovery since TCM syndrome differentiation is involved
in diagnosis and treatment in TCM practice. All natural products
can act as drugs for the treatment of disease when they are found
effective in certain patients with corresponding TCM syndrome,
and such approaches focus on tailoring drug treatment prescribed
to the patients. Thus it is possible to ﬁnd new indication of a cer-
tain drug in a clinical trial based on TCM syndrome differentiation
concept. Consecutive clinical trials can be employed to ﬁnd “new”
drugs by revealing the TCM syndrome related indications of exist-
ing “old” drugs. As shown in the right part of Fig. 3, the ﬁndings
of the new indication can be realized by determining what are
positively or negatively related to the effectiveness. The correlated
factors could be obtained by comparing the differences between the
effective cases and non-effective cases in the view of syndrome dif-
ferentiation. Our previous study showed that RA patients with cold
syndrome had a signiﬁcantly higher response rate to the biomedical
therapy (consisting of diclofenac, methotrexate, and sulfasalazine)
than RA patients with hot syndrome (Lu et al., 2009), and this can
give rise to the therapy that could lead to a new drug discovery
since its indication was  redeﬁned with the TCM cold syndrome. All
medicines should be rigorously tested in the clinical trials (Angell
and Kassirer, 1998; Tsang, 2007), and potential clinical trials based
on TCM syndrome differentiation could be a way for new drug
development by referring to the biomedical disease indications.
Network pharmacology, a systems biology based methodology,
is a new TCM approach to drug design that encompasses the con-
struction of disease network, drug–target network, drug–disease
network. It offers the concept of drug discovery that simultaneously
considers the improvement of clinical efﬁcacy and reduction of side
effects and toxicity, which are the most important reasons for fail-
ure in R&D of new drug (Sams-Dodd, 2005; Hopkins, 2008). Based
on TCM network pharmacology, the molecular network of disease
diagnosed by TCM syndrome and pharmacological network that
relates the herbal formula (mainly multiple herbal compounds) are
important key factors for consideration. Information for a disease
could be collected and accumulated to build up the molecular net-
work of that particular disease as identiﬁed in orthodox medicine.
For example, the molecular network has been built up on rheuma-
toid arthritis (RA) (Wu et al., 2010). The network of a disease could
be linked to locate the corresponding pharmacological network
of drug treatment (intervention) by merging the disease network
with the intervention network. In recent years, scientists focused
on the molecular network build-up using TCM pattern differenti-
ation for certain diseases (Zhao et al., 2010). For instance, RA can
be differentiated into two  major TCM patterns: cold and hot pat-
terns, which can be shown in terms of molecular networks (Jiang
et al., 2011a). Separate TCM formula used for intervention of RA of
cold or hot patterns, with multiple herbal compounds, are targeting
on separate biological networks pharmacologically. Thus building-
up of pharmacological network of TCM formula is a good way to
ﬁnd new potential multiple compound medicines for a TCM syn-
drome in a disease or new targeted TCM syndrome for an “old” drug.
Advance information on genomics, proteomics and metabolomics
has enabled scientists to correlate proper methodology for building
up the molecular pharmacological network in combinational TCM
therapy. For example, we  have successfully combined text-mining
with bioinformatics to build up the functional networks for Salvia
miltiorrhiza radix (SM) and Panax notoginseng radix (PN) combi-
nation in the TCM intervention of coronary heart diseases by the
SM–PN herbal-pair formula (Gao and Aiping, 2011).
By linking the molecular disease network, TCM syndrome with
the pharmacological network of the potential TCM formula, we can
locate which formula would be the best in treating the disease
with the identiﬁed TCM syndrome and in terms of molecular dis-
ease network. Such approach will further help to choose the right
M. Jiang et al. / Journal of Ethnopharmacology 140 (2012) 634– 642 639
Fig. 4. Application of TCM syndrome differentiation and new drug discovery. A patient with a certain disease associated with TCM syndrome may  show certain characteristics
in  the disease-based network and syndrome characteristics in TCM syndrome network. Based on the network pharmacology of a drug built up by systems biology approaches,
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ith  the characteristics in the TCM syndrome network in a disease-based network
olecular networks of TCM syndrome A, B and C in the disease respectively.
ew drug candidates for further pre-clinical study (discovering new
hemical compounds) or clinical study (for deﬁning the new indi-
ation with TCM syndrome for that “old” drug). As shown in Fig. 4,
CM syndrome differentiation network incorporated in the disease
iological network can: generate the investigating path for poten-
ial drug candidates or locate existing “old” drugs via the merging
f TCM syndrome with identiﬁed disease biological network and
dentify the pharmacological networks of tested candidates. More
mportantly, there are many herbal formulas such as the SM–PN
erbal pair, and the herbal formulas would be a great source for
ew multiple compound drug discovery. The network pharmacol-
gy would be helpful in ﬁnding the right multiple compound drug
andidates from herbal formula for further new drug development.
. Syndrome differentiation and novel medical equipment
evelopment in TCM
The advances in medical technological diagnosis equipment
sed in monitoring of disease patterns can certainly help mod-
rnization of TCM diagnosis and treatment processes. It is
ecognised that TCM syndrome differentiation is a complicated
nd experience-based process. To have a generalised and agreed
ethod of diagnosis using novel diagnostic equipment on TCM
ongue and pulse diagnosis will assist further development towards
bjective measurement.
Tongue appearance has some speciﬁc features and could be sim-
liﬁed for clear identiﬁcation in clinical practice though there is a
elatively poor consistency in the results of TCM syndrome differen-
iation due to the subjective nature of assessing complicated tongue
ppearance and pulse (G.G. Zhang et al., 2004; Zhang et al., 2005).
revious study suggests that tongue coating and tongue body
olour might be used to help identify a subset of RA patients for cer-
ain interventions (Jiang et al., 2011c).  More efforts are needed for
esearch into the diagnostic equipment for accurate measurement
f the tongue and pulse diagnosis. It was reported that a digital
nalysis instrument for the tongue image can objectively describe
he tongue features of patients with different syndromes of lung
ancer (Su et al., 2011). Efforts have been made to build up a feasi-
le and effective model for pulse analyses in order to facilitate its
linical application. These models were introduced or constructed
ased on an artiﬁcial neural network (Tang et al., 2012), Bayesianse by comparing and merging the pharmacological network of a new drug candidate
harmacological networks of potential candidate A, B and C were merged with the
networks (Wang and Cheng, 2005) and the ensemble empirical
mode decomposition (Yan et al., 2011).
Comprehensive equipment or diagnostic systems on “com-
bination of four examination methods, including inspection,
auscultation, interrogation, and pulse-feeling and palpation” for
TCM syndrome differentiation are being developed by integrating
modern medical techniques. One such system had entered the mar-
ket in China last year (http://www.daosh.com/s.asp?id=79). The
feasibility and usefulness of this system is being tested. We  believe
that from this launch, more novel diagnostic equipment for TCM
syndrome differentiation will be developed and assessed for their
usefulness in TCM syndrome differentiation in the near future.
7. Major issues in modern TCM syndrome differentiation
research
TCM focuses attention to the integrity of the whole human
body and its interrelationship with nature. The component parts of
the human body are inseparable and are functionally coordinative
and mutually beneﬁcial whilst affecting each other pathologically.
Modern biomedical research has entered an era of integrating
various research technologies and methods to analyse difﬁcult bio-
logical problems at molecular level as a whole, which is shown
by studies in terms of genomics, metabolomics and proteomics.
Accordingly the application of molecular biology is to study life
phenomena and nature of diseases, governing and controlling the
development and progression of systems processes. Thus modern
research on TCM syndrome differentiation should lead to better
progress and understanding of TCM diagnostic approaches. How-
ever, there has been few progress in research based on the modern
TCM syndrome differentiation. Recently more issues have been
taken into consideration for clinical trial design, systems biol-
ogy technique application and data mining approach applications.
These will form the major areas for the improvement of modern
TCM syndrome differentiation research.
The key challenge in TCM syndrome differentiation research is
how to standardize the diagnostic procedure for syndrome. TCM
syndrome is differentiated from the clinical manifestations, and
the diversiﬁed manifestations would make the TCM syndrome
in a patient appearing in syndrome combination or mixed syn-
dromes (we  can deﬁne the simple syndrome as a syndrome unit
in a patient). Some clinical manifestations for TCM syndrome
6 opharm
d
p
s
T
c
i
c
R
d
a
s
i
o
e
s
T
t
f
f
r
T
t
v
s
f
l
T
m
t
b
m
i
t
c
o
e
d
i
r
f
o
a
i
(
d
o
r
o
d
o
t
b
g
m
s
i
2
t
d
t
f
m
v40 M. Jiang et al. / Journal of Ethn
ifferentiation are subjective, such as pulse feelings, which might
rovide different understandings about the pulse feelings in the
yndrome differentiation by different doctors. Therefore modern
CM syndrome differentiation research should focus on the typi-
al (easy to be differentiated) and most important TCM syndromes
n a disease. For example, RA syndrome research should focus on
old and hot syndrome as they are most important syndromes for
A, similarly Xue-Yu syndrome should be related to coronary heart
isease. In some instance, major objective clinical manifestations
re considered as bases for TCM syndrome differentiation under-
tandable and simpler. For example, the cold and hot syndromes
n RA were differentiated by analysing 13 symptoms, which are
bjective measures in the score scale system as assessment for
valuation purposes (Lu et al., 2009). Another way for modern TCM
yndrome differentiation research is to deﬁne the corresponding
CM syndrome when it has positively responded to the interven-
ion (drug treatment or other therapy). In TCM, the choice of herbal
ormula is closely related to the TCM syndrome, that is, the herbal
ormula must be effective in treating the patients if they are cor-
ectly differentiated according to TCM syndrome. Similarly, the
CM syndrome in the responsive case to an intervention should be
he corresponding TCM syndrome for that intervention. At present
ery limited examples can be identiﬁed to be corresponding to TCM
yndrome for many interventions (biomedicines included). There-
ore the exploration of TCM syndrome via clinical trials that are
inked to biomedical diagnosis should be the key topics in modern
CM syndrome differentiation research.
A properly conducted clinical trial is one of the most important
ethods that measure the success of conventional medical prac-
ice and clinical trials involving TCM syndrome differentiation will
e the most important method to assess the efﬁcacy of TCM treat-
ent in the future. Due to the complicated and experience-based
nvolvement in the TCM syndrome differentiation, it is preferable
o start the TCM syndrome differentiation research at a level that
an be incorporated in clinical trial to demonstrate the importance
f stratiﬁcation into different TCM syndromes amongst patients. An
xample to illustrate such approach would be to focus on the RA, a
isease that has deﬁnite measureable clinical/biomedical features
n conventional medical practice. TCM syndrome differentiation
elated information can be collected from thousands of RA patients
rom either expert consensus on the TCM syndrome differentiation
r from TCM syndrome differentiation generated using statistical
nalysis (Li et al., 2006; Lu, 2006). This two stage clinical trial design
ncluding TCM syndrome differentiation concept can be integrated
Lu and Li, 2010; Zhang et al., 2011) into the clinical trial (see Fig. 4).
Systems biology is a general trend of contemporary scientiﬁc
evelopment (Wang et al., 2009). The advances of the “Omics” rev-
lution and methodology in the post-genomic era of life science
esearch, bioinformatics and systems biology have all collectively
ffered an opportunity to integrate multi-dimensional and multiple
ata from medical practices. The capturing of these unprecedented
pportunities and challenges will provide a platform for research
o understanding of the principles of TCM practice. Thus systems
iology approaches are expected to open the way to a new conver-
ence of TCM syndrome differentiation information. By analysing
icroarray, metabolomic data obtained from literature, the TCM
yndrome differentiation could be related to biomarkers or biolog-
cal networks (Cheng et al., in press; Jiang et al., 2011a; A. Lu et al.,
011). Furthermore, systems biology approaches can assist in iden-
ifying the therapeutic mechanism of multiple component herbal
rugs, including the build-up of the pharmacological networks of
he herbal drugs, which can be merged with the TCM syndrome dif-
erentiation network in certain diseases to explore the therapeutic
echanism and the biomarkers for speciﬁc indication.
Confronted with the increasing popularity of TCM and the huge
olume of TCM data, both historically accumulated and recentlyacology 140 (2012) 634– 642
obtained, there is an urgent need to explore these resources effec-
tively by the techniques of knowledge discovery in database (KDD)
(Feng et al., 2006). A series of KDD methods are used in existing
knowledge discovery in TCM researches, ranging from conven-
tional frequent item set mining to state of the art latent structure
models. Yet few or no obvious progress has been made in TCM
practice with KDD techniques. Thus the integrated data min-
ing approaches should be used with the extensively integrated
databases, such as the TCM data base in Chinese patients with
TCM syndrome differentiation and clinical observation, accumu-
lated case reports in the TCM clinical practice, PubMed in English
on biomedicine, and PubChem in English on herbal chemistry and
protein targets. We  believe that integrated data mining approach
application in analysis of the integrated TCM and biomedical
and chemical databases would lead to progress in modern TCM
research. These may  include: the ﬁnding of the basic rule for herbal
prescription targeting to the corresponding TCM syndrome differ-
entiation in a certain disease, the build-up of the biological network
of the disease, and the potential pharmacological network of the
herbal prescription.
8. Concluding remarks
Over the past decades, we have identiﬁed increasing numbers
of clinical trials on TCM treatment efﬁcacy with unsatisfactory RCT
designs due mainly to the lack of stratiﬁcation using TCM syndrome
differentiation. We  expect higher quality RCT in the future to meet
the needs of modern research and development. Such approaches
will add more weight to the evidence-based medical practice in
TCM. However, it is crucial that the concept of TCM syndrome dif-
ferentiation should be made understood and substantiated with
biomedical evidence in the medical science arena. We have initi-
ated some background work in these areas. Published data have also
been initiated by biomedical scientists and researchers in China and
worldwide to provide information towards these directions. More
effort will be required to substantiate such ﬁndings to support the
concepts.
The TCM syndrome differentiation uses phenotype-like clini-
cal manifestation to classify patients, which would further assist
in stratiﬁcation for the intervention in order to improve the efﬁ-
cacy of the intervention based on the TCM syndrome differentiation
related clinical trial strategy. Research in TCM syndrome differ-
entiation will provide the basis of the molecular network of TCM
syndrome differentiation for certain disease types, which will assist
in deﬁning the potential mechanism of Chinese herbal medicines.
The incorporation of TCM syndrome differentiation into biomed-
ical disease diagnosis will lead to a new era in the development
of medical sciences to research in the diagnosis, clinical trial, and
new drug discovery in TCM. The way forward to identify evidence-
base of TCM syndrome differentiation in TCM practice requires
multidisciplinary collaborations amongst different professionals,
researchers and scientists of both conventional medical and TCM
practices with expertise from biomedical, bioinformatics, medical,
pharmaceutical and TCM disciplines.
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Glossary
Syndrome: also called Zheng.  It is a state deﬁned by TCM based on its own theory
after analysis on the symptoms, tongue appearance and pulse feelings.
Syndrome differentiation: also called Bian Zheng,  or pattern classiﬁcation. It is a process
to  deﬁne the syndrome (Zheng).
Bian Zheng Lun Zhi: it means treatment based on Syndrome Differentiation.
Shen deﬁciency syndrome: one kind of TCM syndromes. It is also called kidney deﬁ-
ciency syndrome, and it can be classiﬁed into 2 major categories, kidney Yang
deﬁciency and kidney Yin deﬁciency.
Shen Yang deﬁciency syndrome: one kind of TCM syndromes, and also called kidney
Yang deﬁciency syndrome.
Shen Yin deﬁciency syndrome: one kind of TCM syndromes, and also called kidney Yin
deﬁciency syndrome.
Xue-Yu syndrome: one kind of TCM syndromes, and also called blood stasis syndrome.
Fufang: TCM herbal formulae.
Han/Re syndrome: two kinds of TCM syndromes with opposite clinical manifesta-
tions, also called cold/hot syndrome,  or cold/heat syndrome.
I-Yin deﬁciency syndrome: also called Deﬁciency of both I and Yin syndrome.  It is a
combined TCM syndrome consisted of manifestations on both I deﬁciency and
Yin  deﬁciency syndromes.
I  deﬁciency syndrome: one kind of TCM syndromes.
Shi-Re accumulation interior syndrome: one kind of TCM syndromes. It is also called
TCM syndrome of damp-heat accumulation interior.
Tan-Re zoo Fei syndrome: one kind of TCM syndrome, and also called phlegm-heat
blocking Fei (Lung) syndromei.
Xue-Re syndrome: one kind of TCM syndromes, and also called blood-heat syndrome.
Shi-Re syndrome: one kind of TCM syndromes, and also called damp-heat obstruction
syndrome.
Pi-CSU syndrome: one kind of TCM syndrome, and also called spleen deﬁciency syn-
drome.
Qi-Xu and Xue-Yu syndrome: one kind of TCM syndrome, and also called Qi deﬁciency
and  blood stasis syndrome.
Lizhong Pill: one type of TCM proprietary medicines.
Tanreqing Injection: one type of TCM proprietary medicines.
Buyang Huanwu Tang: also called Buyang Huanwu decoction. It is a TCM formula.
Fufangkushen enteric-coated capsule: one type of TCM proprietary medicines.
